Progress in drug formulation design and delivery of medicinal substances used in ophthalmology

Wróblewska, K.; Jadach, Barbara; Muszalska-Kolos, Izabela

doi:10.1016/j.ijpharm.2021.121012

Cited by 17 publications

(15 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 19 , 26 , 27 , 29 , 33 – 36 Table 1 catalogs the approved nanotechnology-based topical ophthalmic formulations and those under clinical trial. 2 – 5 , 12 , 16 , 18 – 20 , 26 – 30 , 32 , 33 , 37 – 45 …”

Section: Nanotechnology-based Formulationsmentioning

confidence: 99%

“…Traditional methods of administration, such as the topical instillation or systemic administration, present significant limitations, in terms of intraocular permeability or concurrent side effects, which are mainly related to the frequency of the dosing scheme and systemic exposure. 2 , 18 …”

Section: Future Prospectsmentioning

confidence: 99%

“… 74 To sum up, the imminent prospects are immense, potential to ‘start a brave, new chapter’ in therapeutics, only human antigen R is involved in a variety of pathologies, such as cancer, cardiovascular diseases, and chronic inflammation. 4 , 18 , 29 , 40 , 69 , 71 , 74 …”

Section: Future Prospectsmentioning

confidence: 99%

“…Gels, however, achieve only a limited improvement in bioavailability, and the dosing frequency can be decreased to once a day at most. 17 , 18 Prodrug is a chemically modified molecule of the active substance to enhance its lipophilicity to facilitate corneal permeability. Subsequently, it is metabolized enzymatically to the pharmacologically active compound.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Nanotechnology-based formulations to amplify intraocular bioavailability

2022

View full text Add to dashboard Cite

Conventional drug delivery formulations, such as eye drops and ointments, are mainly administered by topical instillation. The topical delivery of ophthalmic drugs is a challenging endeavor despite the eye is easily accessible. Unique and complex barriers, serving as protection against extrinsic harmful factors, hamper therapeutic intraocular drug concentrations. Bioavailability for deeper ocular tissues of the anterior segment of the eye is exceptionally low. As the bioavailability of the active substance is the major hurdle to overcome, dosing is increased, so the side effects do. Both provoke patient poor compliance, confining the desired therapeutic outcome. The incidence and severity of adverse reactions amplify evenly in the case of chronic treatments. Current research focuses on the development of innovative delivery strategies to address low ocular bioavailability and provide safe and convenient dosing schemes. The main objective of this review is to explore and present the latest developments in ocular drug delivery formulations for the treatment of the pathology of the anterior segment of the eye. Nanotechnology-based formulations, that is, organic nanoparticles (liposomes, niosomes/discosomes, dendrimers, nanoemulsions, nanosuspensions, nanoparticles/nanospheres) and inorganic nanoparticles, nanoparticle-laden therapeutic contact lenses, in situ gelling systems, and ocular inserts, are summarized and presented accordingly.

show abstract

Section: Nanotechnology-based Formulationsmentioning

confidence: 99%

Section: Future Prospectsmentioning

confidence: 99%

Section: Future Prospectsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Nanotechnology-based formulations to amplify intraocular bioavailability

2022

View full text Add to dashboard Cite

show abstract

“…Furthermore, bacterial keratitis is one of the most important causes of visual impairment and corneal blindness all over the world. , It has been reported that the principal pathogens associated with bacterial keratitis are Staphylococcus aureus and Pseudomonas aeruginosa. , Topically applied eye drops are the most common administration of drugs in ocular infection . However, poor ocular bioavailability of conventional eye drops is an intractable problem in the treatment of bacterial keratitis due to the physical and physiological barriers of the eye, including poor corneal permeability, dilution of the drug in the tear film, and nasolacrimal duct drainage, which significantly reduces drug exposure time. − Therefore, effective treatment of bacterial keratitis strictly requires frequent and repeated application of one or more eye drops, which may lead to poor patient compliance and undesirable side effects …”

Section: Introductionmentioning

confidence: 99%

Surface Self-Assembly Construction of Therapeutic Contact Lens with Bacterial “Kill-Releasing” and Drug-Reloading Capabilities for Efficient Bacterial Keratitis Treatment

Wen

Chen

Shen

et al. 2022

ACS Biomater. Sci. Eng.

View full text Add to dashboard Cite

Bacterial keratitis, an ophthalmic emergency, can cause corneal perforation and even endophthalmitis, thus leading to severe visual impairment. To achieve effective treatment of bacterial keratitis, good bioavailability of antimicrobial drugs on the ocular surface is desired. In this investigation, a layer-by-layer (LBL) self-assembly combined with the host–guest recognition was used to construct an antibacterial coating on the surface of corneal contact lens (CLs) to improve drug bioavailability and achieve successful treatment of bacterial keratitis. First, a radical copolymerization of acrylic acid (AA) and 1-adamantan-1-ylmethyl acrylate (AdA) was carried out to synthesize a polyanionic copolymer P(AA-co-AdA) (defined as PAcA). Then, PAcA copolymer combined with poly(ethyleneimine) (PEI) was used for a layer-by-layer (LBL) self-assembly to fabricate multilayer films on the surface of CLs. An antibacterial conjugate, β-cyclodextrin–levofloxacin (β-CD-LEV), was successfully synthesized and utilized to generate antibacterial coating through a host–guest interaction between AdA and β-CD-LEV. The antibacterial ability and treatment effect of bacterial keratitis was evaluated by in vitro assay and in vivo test in an animal model of staphylococcal keratitis, demonstrating that the antibacterial coating had good antibacterial and germicidal efficacy both in vivo and in vitro. We believe that this work will provide a promising strategy for the treatment of bacterial keratitis.

show abstract